Anything under a cheeky dollar this is a steal, page-28

A Phase II, Multicenter, Double-Blinded, Randomized, Placebo-Controlled, Parallel-Group, Single-Dose Study to Determine the Safety, Preliminary Efficacy, and Pharmacokinetics of ARG-007 in Acute Ischemic Stroke Patients

https://anzctr.org.au/Trial/Registration/TrialReview.aspx?id=385922&isReview=true

So in hospital only LVO suitable for thromectomy (so after CTP/CTA), <24hr from onset, no established core/hemorrhage (ASPECT 0-5).

Follow the above link for further such as eligibility criteria, looks like to be in Hospital IV admin.

As you may know (those that follow the other) I'm heavily invested in EMV, I'm still on the fence about this one, I think results are encouraging (aren't most of them that pass into Phase 2) and the TAM is huge (aren't most of them). Many drugs fail in Phase 2 (empirical evidence, posted examples on the media thread before), but I WANT this one to succeed (don't we all).
So I'm not sure how I have an edge on this, EMV I've spoken with and seen in detail, (I haven't been able to contact AGN, albeit Liz may have been busy - probably should try again, maybe my email went into her SPAM).
I lightened going into the immediate pervious rally, but would consider accumulating if we test historical lows (would only happen if we don't get consistent news flow on Phase 2, bad results or market general crash - the later I would then have attention for my allocated of capital in many directions...)
Risks that it will drift up on no news (more likely drift down), taken over?? that might be on Phase 2 results in

It would be very pleasing to see an Australian invention make it large. Currently estimated last date on the trail website is Oct 2025, last data 2026, maybe I could put some of my EMV unicorn* (by then) into AGN!

*joke, not promotion.




And this is a link to their phase 1
https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=ACTRN12622001209785